|
1
|
Ostrom QT, Gittleman H, Fulop J, Liu M,
Blanda R, Kromer C, Wolinsky Y, Kruchko C and Barnholtz-Sloan JS:
CBTRUS statistical report: Primary brain and central nervous system
tumors diagnosed in the United States in 2008–2012. Neurooncol.
17(Suppl 4): iv1–iv62. 2015.
|
|
2
|
Louis DN, Perry A, Reifenberger G, von
Deimling A, Figarella-Branger D, Cavenee WK, Ohgaki H, Wiestler OD,
Kleihues P and Ellison DW: The 2016 World Health Organization
classification of tumors of the central nervous system: A summary.
Acta Neuropathol. 131:803–820. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Taylor MD, Northcott PA, Korshunov A,
Remke M, Cho Y-J, Clifford SC, Eberhart CG, Parsons DW, Rutkowski
S, Gajjar A, et al: Molecular subgroups of medulloblastoma: The
current consensus. Acta Neuropathol. 123:465–472. 2012. View Article : Google Scholar :
|
|
4
|
Robinson G, Parker M, Kranenburg TA, Lu C,
Chen X, Ding L, Phoenix TN, Hedlund E, Wei L, Zhu X, et al: Novel
mutations target distinct subgroups of medulloblastoma. Nature.
488:43–48. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Gajjar A, Chintagumpala M, Ashley D,
Kellie S, Kun LE, Merchant TE, Woo S, Wheeler G, Ahern V, Krasin
MJ, et al: Risk-adapted craniospinal radiotherapy followed by
high-dose chemotherapy and stem-cell rescue in children with newly
diagnosed medulloblastoma (St Jude Medulloblastoma-96): Long-term
results from a prospective, multicentre trial. Lancet Oncol.
7:813–820. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Northcott PA, Jones DT, Kool M, Robinson
GW, Gilbertson RJ, Cho Y-J, Pomeroy SL, Korshunov A, Lichter P,
Taylor MD, et al: Medulloblastomics: The end of the beginning. Nat
Rev Cancer. 12:818–834. 2012. View
Article : Google Scholar : PubMed/NCBI
|
|
7
|
von Hoff K, Hinkes B, Gerber NU, Deinlein
F, Mittler U, Urban C, Benesch M, Warmuth-Metz M, Soerensen N,
Zwiener I, et al: Long-term outcome and clinical prognostic factors
in children with medulloblastoma treated in the prospective
randomised multicentre trial HIT'91. Eur J Cancer. 45:1209–1217.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Hunter CA and Jones SA: IL-6 as a keystone
cytokine in health and disease. Nat Immunol. 16:448–457. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Grivennikov SI and Karin M: Inflammatory
cytokines in cancer: Tumour necrosis factor and interleukin 6 take
the stage. Ann Rheum Dis. 70(Suppl 1): i104–i108. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Chang CH, Hsiao CF, Yeh YM, Chang GC, Tsai
YH, Chen YM, Huang MS, Chen HL, Li YJ, Yang PC, et al: Circulating
interleukin-6 level is a prognostic marker for survival in advanced
nonsmall cell lung cancer patients treated with chemotherapy. Int J
Cancer. 132:1977–1985. 2013. View Article : Google Scholar
|
|
11
|
Grivennikov S, Karin E, Terzic J, Mucida
D, Yu G-Y, Vallabhapurapu S, Scheller J, Rose-John S, Cheroutre H,
Eckmann L, et al: IL-6 and Stat3 are required for survival of
intestinal epithelial cells and development of colitis-associated
cancer. Cancer Cell. 15:103–113. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Yeoh GC, Ernst M, Rose-John S, Akhurst B,
Payne C, Long S, Alexander W, Croker B, Grail D and Matthews VB:
Opposing roles of gp130-mediated STAT-3 and ERK-1/2 signaling in
liver progenitor cell migration and proliferation. Hepatology.
45:486–494. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Wegiel B, Bjartell A, Culig Z and Persson
JL: Interleukin-6 activates PI3K/Akt pathway and regulates cyclin
A1 to promote prostate cancer cell survival. Int J Cancer.
122:1521–1529. 2008. View Article : Google Scholar
|
|
14
|
Wei L-H, Kuo M-L, Chen C-A, Chou C-H, Lai
K-B, Lee C-N and Hsieh C-Y: Interleukin-6 promotes cervical tumor
growth by VEGF-dependent angiogenesis via a STAT3 pathway.
Oncogene. 22:1517–1527. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Oh K, Lee O-Y, Shon SY, Nam O, Ryu PM, Seo
MW and Lee D-S: A mutual activation loop between breast cancer
cells and myeloid-derived suppressor cells facilitates spontaneous
metastasis through IL-6 trans-signaling in a murine model. Breast
Cancer Res. 15:R792013. View
Article : Google Scholar : PubMed/NCBI
|
|
16
|
Zou M, Zhang X and Xu C: IL6-induced
metastasis modulators p-STAT3, MMP-2 and MMP-9 are targets of
3,3′-diindolylmethane in ovarian cancer cells. Cell Oncol (Dordr).
39:47–57. 2016. View Article : Google Scholar
|
|
17
|
Mauer J, Denson JL and Brüning JC:
Versatile functions for IL-6 in metabolism and cancer. Trends
Immunol. 36:92–101. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Taga T and Kishimoto T: Gp130 and the
interleukin-6 family of cytokines. Annu Rev Immunol. 15:797–819.
1997. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Miura T, Mitsunaga S, Ikeda M, Shimizu S,
Ohno I, Takahashi H, Furuse J, Inagaki M, Higashi S, Kato H, et al:
Characterization of patients with advanced pancreatic cancer and
high serum interleukin-6 levels. Pancreas. 44:756–763. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Nakashima J, Tachibana M, Horiguchi Y, Oya
M, Ohigashi T, Asakura H and Murai M: Serum interleukin 6 as a
prognostic factor in patients with prostate cancer. Clin Cancer
Res. 6:2702–2706. 2000.PubMed/NCBI
|
|
21
|
Dethlefsen C, Højfeldt G and Hojman P: The
role of intratumoral and systemic IL-6 in breast cancer. Breast
Cancer Res Treat. 138:657–664. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Hibi M, Murakami M, Saito M, Hirano T,
Taga T and Kishimoto T: Molecular cloning and expression of an IL-6
signal transducer, gp130. Cell. 63:1149–1157. 1990. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Mihara M, Hashizume M, Yoshida H, Suzuki M
and Shiina M: IL-6/IL-6 receptor system and its role in
physiological and pathological conditions. Clin Sci (Lond).
122:143–159. 2012. View Article : Google Scholar
|
|
24
|
Leu C-M, Wong F-H, Chang C, Huang S-F and
Hu CP: Interleukin-6 acts as an antiapoptotic factor in human
esophageal carcinoma cells through the activation of both STAT3 and
mitogen-activated protein kinase pathways. Oncogene. 22:7809–7818.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Jones SA, Scheller J and Rose-John S:
Therapeutic strategies for the clinical blockade of IL-6/gp130
signaling. J Clin Invest. 121:3375–3383. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Garbers C, Aparicio-Siegmund S and
Rose-John S: The IL-6/gp130/STAT3 signaling axis: Recent advances
towards specific inhibition. Curr Opin Immunol. 34:75–82. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Roxburgh CS and McMillan DC: Therapeutics
targeting innate immune/inflammatory responses through the
interleukin-6/JAK/STAT signal transduction pathway in patients with
cancer. Transl Res. 167:61–66. 2016. View Article : Google Scholar
|
|
28
|
Yao X, Huang J, Zhong H, Shen N, Faggioni
R, Fung M and Yao Y: Targeting interleukin-6 in inflammatory
autoimmune diseases and cancers. Pharmacol Ther. 141:125–139. 2014.
View Article : Google Scholar
|
|
29
|
Xu S and Neamati N: gp130: a promising
drug target for cancer therapy. Expert Opin Ther Targets.
17:1303–1328. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Bournazou E and Bromberg J: Targeting the
tumor microenvironment: JAK-STAT3 signaling. JAK-STAT.
2:e238282013. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Heo T-H, Wahler J and Suh N: Potential
therapeutic implications of IL-6/IL-6R/gp130-targeting agents in
breast cancer. Oncotarget. 7:15460–15473. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Wang S-W and Sun Y-M: The IL-6/JAK/STAT3
pathway: Potential therapeutic strategies in treating colorectal
cancer (Review). Int J Oncol. 44:1032–1040. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Calabrese LH and Rose-John S: IL-6
biology: Implications for clinical targeting in rheumatic disease.
Nat Rev Rheumatol. 10:720–727. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Tanaka T, Narazaki M and Kishimoto T:
Therapeutic targeting of the interleukin-6 receptor. Annu Rev
Pharmacol Toxicol. 52:199–219. 2012. View Article : Google Scholar
|
|
35
|
Li H, Xiao H, Lin L, Jou D, Kumari V, Lin
J and Li C: Drug design targeting protein-protein interactions
(PPIs) using multiple ligand simultaneous docking (MLSD) and drug
repositioning: Discovery of raloxifene and bazedoxifene as novel
inhibitors of IL-6/GP130 interface. J Med Chem. 57:632–641. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Wu X, Cao Y, Xiao H, Li C and Lin J:
Bazedoxifene as a novel GP130 inhibitor for pancreatic cancer
therapy. Mol Cancer Ther. 15:2609–2619. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Franken NA, Rodermond HM, Stap J, Haveman
J and van Bree C: Clonogenic assay of cells in vitro. Nat Protoc.
1:2315–2319. 2006. View Article : Google Scholar
|
|
38
|
Racker E: Bioenergetics and the problem of
tumor growth. Am Sci. 60:56–63. 1972.PubMed/NCBI
|
|
39
|
Koppenol WH, Bounds PL and Dang CV: Otto
Warburg's contributions to current concepts of cancer metabolism.
Nat Rev Cancer. 11:325–337. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Jozwiak J, Grajkowska W and Wlodarski P:
Pathogenesis of medulloblastoma and current treatment outlook. Med
Res Rev. 27:869–890. 2007. View Article : Google Scholar
|
|
41
|
Massimino M, Cefalo G, Riva D, Biassoni V,
Spreafico F, Pecori E, Poggi G, Collini P, Pollo B, Valentini L, et
al: Long-term results of combined preradiation chemotherapy and
age-tailored radiotherapy doses for childhood medulloblastoma. J
Neurooncol. 108:163–171. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Packer RJ, Sutton LN, Elterman R, Lange B,
Goldwein J, Nicholson HS, Mulne L, Boyett J, D'Angio G,
Wechsler-Jentzsch K, et al: Outcome for children with
medulloblastoma treated with radiation and cisplatin, CCNU, and
vincristine chemotherapy. J Neurosurg. 81:690–698. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Rutkauskiene G and Labanauskas L:
Treatment of patients of high-risk group of medulloblastoma with
the adjuvant lomustine, cisplatin, and vincristine chemotherapy.
Medicina (Kaunas). 41:1026–1034. 2005.
|
|
44
|
Rood BR, MacDonald TJ and Packer RJ:
Current treatment of medulloblastoma: Recent advances and future
challenges. Semin Oncol. 31:666–675. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Samkari A, White JC and Packer RJ:
Medulloblastoma: Toward biologically based management. Semin
Pediatr Neurol. 22:6–13. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Zanotto-Filho A, Gonçalves RM, Klafke K,
de Souza PO, Dillenburg FC, Carro L, Gelain DP and Moreira JCF:
Inflammatory landscape of human brain tumors reveals an NFκB
dependent cytokine pathway associated with mesenchymal
glioblastoma. Cancer Lett. 390:176–187. 2017. View Article : Google Scholar
|
|
47
|
Liu Q, Li G, Li R, Shen J, He Q, Deng L,
Zhang C and Zhang J: IL-6 promotion of glioblastoma cell invasion
and angiogenesis in U251 and T98G cell lines. J Neurooncol.
100:165–176. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Kumari N, Dwarakanath BS, Das A and Bhatt
AN: Role of interleukin-6 in cancer progression and therapeutic
resistance. Tumour Biol. 37:11553–11572. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Ball S, Li C, Li P-K and Lin J: The small
molecule, LLL12, inhibits STAT3 phosphorylation and induces
apoptosis in medulloblastoma and glioblastoma cells. PLoS One.
6:e188202011. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Heinrich PC, Behrmann I, Haan S, Hermanns
HM, Müller-Newen G and Schaper F: Principles of interleukin
(IL)-6-type cytokine signalling and its regulation. Biochem J.
374:1–20. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Chines AA and Komm BS: Bazedoxifene
acetate: A novel selective estrogen receptor modulator for the
prevention and treatment of postmenopausal osteoporosis. Drugs
Today. 45:507–520. 2009.PubMed/NCBI
|
|
52
|
Komm BS, Kharode YP, Bodine PV, Harris HA,
Miller CP and Lyttle CR: Bazedoxifene acetate: A selective estrogen
receptor modulator with improved selectivity. Endocrinology.
146:3999–4008. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Archer DF, Pinkerton JV, Utian WH,
Menegoci JC, de Villiers TJ, Yuen CK, Levine AB, Chines AA and
Constantine GD: Bazedoxifene, a selective estrogen receptor
modulator: Effects on the endometrium, ovaries, and breast from a
randomized controlled trial in osteoporotic postmenopausal women.
Menopause. 16:1109–1115. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Palacios S, de Villiers TJ, Nardone FC,
Levine AB, Williams R, Hines T, Mirkin S and Chines AA: Assessment
of the safety of long-term bazedoxifene treatment on the
reproductive tract in postmenopausal women with osteoporosis:
Results of a 7-year, randomized, placebo-controlled, phase 3 study.
Maturitas. 76:81–87. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Vander Heiden MG, Cantley LC and Thompson
CB: Understanding the Warburg effect: The metabolic requirements of
cell proliferation. Science. 324:1029–1033. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Ando M, Uehara I, Kogure K, Asano Y,
Nakajima W, Abe Y, Kawauchi K and Tanaka N: Interleukin 6 enhances
glycolysis through expression of the glycolytic enzymes hexokinase
2 and 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase-3. J
Nippon Med Sch. 77:97–105. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Han J, Meng Q, Xi Q, Zhang Y, Zhuang Q,
Han Y, Jiang Y, Ding Q and Wu G: Interleukin-6 stimulates aerobic
glycolysis by regulating PFKFB3 at early stage of colorectal
cancer. Int J Oncol. 48:215–224. 2016.
|
|
58
|
Ciriza I, Carrero P, Azcoitia I, Lundeen
SG and Garcia-Segura LM: Selective estrogen receptor modulators
protect hippocampal neurons from kainic acid excitotoxicity:
Differences with the effect of estradiol. J Neurobiol. 61:209–221.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Castelló-Ruiz M, Torregrosa G, Burguete
MC, Miranda FJ, Centeno JM, López-Morales MA, Gasull T and Alborch
E: The selective estrogen receptor modulator, bazedoxifene, reduces
ischemic brain damage in male rat. Neurosci Lett. 575:53–57. 2014.
View Article : Google Scholar : PubMed/NCBI
|
